Febuxostat

Independent reference data for Febuxostat (CAS 144060-53-7), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Physicochemical values on record

Documented uses on record

Febuxostat is indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of [allopurinol], who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. It is not recommended for the treatment of asymptomatic hyperuricemia or secondary hyperuricemia.Febuxostat received approval from the Food and Drug Administration (FDA) in 2009.

Synonyms and trade names

Febuxostat; 144060-53-7; Adenuric; Uloric; TMX-67; Tei 6720; Tei-6720; 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid; TMX 67; Zurig; DTXSID8048650; Febuxostatum; NSC-758874; 101V0R1N2E; 2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid; 5-Thiazolecarboxylic acid, 2-(3-cyano-4-(2-methylpropoxy)phenyl)-4-methyl-

Regulatory listings held on file

GHS notification summary	5.9% (1 / 17)

GHS hazard classification

GHS notification summary	5.9% (1 / 17)
Reported hazard statements	H302 (88.2%), H362 (11.8%), H373 (11.8%), H413 (17.6%)

This chemical does not meet GHS hazard criteria for 5.9% (1 of 17) of reports.

H302 (88.2%): Harmful if swallowed [Warning Acute toxicity, oral]

What the public record says

Febuxostat · CAS 144060-53-7 · C16H16N2O3S. UNII 101V0R1N2E. Melting Point: 238-239°; Solubility: <1 mg/mL.

Physical description and handling notes

Source: PubChem / Wikidata; the batch COA governs where values differ.